NexImmune (NEXI)
NASDAQ:NEXI

NexImmune (NEXI) Stock Price & Analysis

84 Followers

NEXI Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$0.19 - $4.91
Previous Close$0.43
Volume125.82K
Average Volume (3M)266.32K
Market CapN/A
Enterprise ValueN/A
Total Cash (Recent Filing)$45.86M
Total Debt (Recent Filing)$1.16M
Price to Earnings (P/E)-0.2
Beta2.60
Next EarningsMar 29, 2023
Next Dividend Ex-DateN/A
Dividend YieldN/A
1Y Price TargetN/A
EPS (TTM)-2.63
Shares Outstanding26,078,451
R-Squared0.16
Standard Deviation0.34
10 Day Avg. Volume124,466
30 Day Avg. Volume266,324
Price to Book (P/B)0.22
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio-0.30
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Price Target UpsideN/A
Rating ConsensusHold
Alpha-0.12
Number of Analyst Covering2


Financials

Annual

Risk Analysis

Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.

---

NEXI FAQ

What was NexImmune’s price range in the past 12 months?
NexImmune lowest stock price was $0.19 and its highest was $4.91 in the past 12 months.
    What is NexImmune’s market cap?
    Currently, no data Available
    When is NexImmune’s upcoming earnings report date?
    NexImmune’s upcoming earnings report date is Mar 29, 2023 which is in 53 days.
      How were NexImmune’s earnings last quarter?
      NexImmune released its earnings results on Nov 14, 2022. The company reported -$0.6 earnings per share for the quarter, beating the consensus estimate of -$0.696 by $0.096.
        Is NexImmune overvalued?
        According to Wall Street analysts NexImmune’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
          Does NexImmune pay dividends?
          NexImmune does not currently pay dividends.
          What is NexImmune’s EPS estimate?
          NexImmune’s EPS estimate is -$0.53.
            How many shares outstanding does NexImmune have?
            NexImmune has 26,078,451 shares outstanding.
              What happened to NexImmune’s price movement after its last earnings report?
              NexImmune reported an EPS of -$0.6 in its last earnings report, beating expectations of -$0.696. Following the earnings report the stock price went down -4.255%.
                Which hedge fund is a major shareholder of NexImmune?
                Among the largest hedge funds holding NexImmune’s share is Slate Path Capital LP. It holds NexImmune’s shares valued at 512K.

                  ---

                  NexImmune Stock Smart Score

                  N/A
                  Not Ranked
                  1
                  2
                  3
                  4
                  5
                  6
                  7
                  8
                  9
                  10

                  Technicals

                  SMA
                  Negative
                  20 days / 200 days
                  Momentum
                  -85.10%
                  12-Months-Change

                  Fundamentals

                  Return on Equity
                  -84.43%
                  Trailing 12-Months
                  Asset Growth
                  -44.83%
                  Trailing 12-Months
                  This stock does not have enough of the key information we need to rate it accurately. Smart Score is calculated for stocks traded in Nasdaq, NYSE, TSE and LSE with a market cap above $30M and average 3 months trading volume above $30K.
                  Learn more about TipRanks Smart Score

                  Company Description

                  NexImmune

                  NexImmune Inc is a clinical-stage biotechnology company engaged in developing immunotherapy to employ body's T cells to generate immune response that mimics natural biology. Its creates therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases.

                  ---

                  Forecast EPS vs Actual EPS


                  Similar Stocks
                  Company
                  Price & Change
                  Follow
                  Yield10 Bioscience
                  Diffusion Pharmaceuticals
                  Bio-Path Holdings
                  Theriva Biologics
                  Silo Pharma

                  Popular Stocks

                  ---
                  What's Included in PREMIUM?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis